Գերմանիա - գերմաներեն - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

riemser pharma gmbh (8146447) - rifampicin - filmtablette - rifampicin (02599) 450 milligramm

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

ebb medical ab - rifampicin - pulver och vätska till infusionsvätska, lösning - 600 mg - rifampicin 600 mg aktiv substans

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

abboxia ab - rifampicin - pulver och vätska till infusionsvätska, lösning - 600 mg - rifampicin 600 mg aktiv substans

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - rifampicin - capsule, hard - 150 milligram(s) - antibiotics; rifampicin

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - rifampicin - capsule, hard - 300 milligram(s) - antibiotics; rifampicin

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 300 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 150 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Վիետնամ - վիետնամերեն - BỘ Y TẾ (CỤC QUẢN LÝ DƯỢC)

ozia pharmaceutical pty. ltd. - rifampicin - viên nang - 150mg

Ռումինիա - ռումիներեն - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

arena group sa - romania - rifampicinum - caps. - 150mg - medicamente pentru tratamentul tuberculozei antibiotice

Շվեդիա - շվեդերեն - Läkemedelsverket (Medical Products Agency)

orifarm ab - rifampicin - kapsel, hård - 300 mg - laktosmonohydrat hjälpämne; propylenglykol hjälpämne; rifampicin 300 mg aktiv substans